Lanean...
Immunotherapy for extensive stage small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive malignancy. Until recently the standard of care for newly diagnosed patients with extensive-stage disease was chemotherapy consisting of etoposide plus a platinum (EP). The median overall survival (OS) was only about 10 months with this systemic therapy...
Gorde:
| Argitaratua izan da: | J Thorac Dis |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
AME Publishing Company
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7656428/ https://ncbi.nlm.nih.gov/pubmed/33209460 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2020.01.37 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|